Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Oncura, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds. Oncura is a unit of GE Healthcare. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Oncura, subject to certain pre-existing vendor agreements, for the treatment of prostate cancer in the U.S. and Canada. The term of the agreement is through May 31, 2013 and provides for additional one-year terms upon mutual agreement of the parties.
"We are pleased to be working with Oncura again," stated M. Christine Jacobs, Chairman and CEO of Theragenics. "We previously supplied Oncura and its predecessors with TheraSeed® from 2000 through 2005. Reestablishing our relationship with Oncura is a testament to the quality and reliability of Theragenics and TheraSeed® in the brachytherapy industry. Oncura has been a leading brachytherapy supplier since 1991, and they bring a unique understanding of the industry."
"We are excited to offer our customers our industry-standard iodine-125 based OncoSeedTM and RAPID Strand™ brands, as well as the leading palladium-103 brand in TheraSeed®," stated Thomas Barker, Urology Product Leader for GE and General Manager of Oncura. "We are pleased to reestablish our relationship with Theragenics who, along with Oncura, is a recognized leader in the advancement of brachytherapy."
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients